- Home
- BEAM vs AKRO Comparison
BEAM vs AKRO Comparison
Compare BEAM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- AKRO
- Stock Information
- Founded
- BEAM 2017
- AKRO 2017
- Country
- BEAM United States
- AKRO United States
- Employees
- BEAM N/A
- AKRO N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- AKRO Health Care
- Exchange
- BEAM Nasdaq
- AKRO Nasdaq
- Market Cap
- BEAM 1.6B
- AKRO 3.9B
- IPO Year
- BEAM 2020
- AKRO 2019
- Fundamental
- Price
- BEAM $19.18
- AKRO $51.52
- Analyst Decision
- BEAM Strong Buy
- AKRO Strong Buy
- Analyst Count
- BEAM 11
- AKRO 6
- Target Price
- BEAM $48.90
- AKRO $82.50
- AVG Volume (30 Days)
- BEAM 2.0M
- AKRO 1.7M
- Earning Date
- BEAM 08-05-2025
- AKRO 08-08-2025
- Dividend Yield
- BEAM N/A
- AKRO N/A
- EPS Growth
- BEAM N/A
- AKRO N/A
- EPS
- BEAM N/A
- AKRO N/A
- Revenue
- BEAM $63,578,000.00
- AKRO N/A
- Revenue This Year
- BEAM N/A
- AKRO N/A
- Revenue Next Year
- BEAM $8.82
- AKRO N/A
- P/E Ratio
- BEAM N/A
- AKRO N/A
- Revenue Growth
- BEAM N/A
- AKRO N/A
- 52 Week Low
- BEAM $13.53
- AKRO $21.34
- 52 Week High
- BEAM $35.25
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- BEAM 60.60
- AKRO 48.23
- Support Level
- BEAM $16.59
- AKRO $51.08
- Resistance Level
- BEAM $20.46
- AKRO $57.35
- Average True Range (ATR)
- BEAM 1.13
- AKRO 2.10
- MACD
- BEAM 0.34
- AKRO -0.83
- Stochastic Oscillator
- BEAM 70.61
- AKRO 14.01
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.